Afelimomab

Afelimomab
Monoclonal antibody
Type F(ab')2 fragment
Source Mouse
Target TNFα
Identifiers
CAS Number 156227-98-4 N
ATC code L04AB03
ChemSpider none
KEGG D07436 YesY
 NYesY (what is this?)  (verify)

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]

References

  1. ↑ Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
  2. ↑ Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine 32 (11): 2173–2182. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.


This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.